the aid library

LIST OPTIONS

Filter

2257

Sort by:

Direction:

Download (1539)

View PDF (2421)

WHO Monographs On Selected Medicinal Plants - Volume 2

World Health Organization WHO (2007) C_WHO

• provide scientific information on the safety, efficacy, and quality control/ quality assurance of widely used medicinal plants, in order to facilitate their appropriate use in Member States; • provide models to assist Member States in developing their own mono- graphs or formularies for these... more

Download (715)

View PDF (167)

Групповая интерперсональная терапия (ипт) при депрессии
recommended

Gerald L. Klerman, Myrna M. Weissman et al. WHO, Columbia University in the city of New York (2018) C_WHO

Данное руководство по применению групповой интерперсональной терапии (групповой ИПТ) в лечении депрессии дополняет собой mental health Gap Action Programme Intervention Guide (mhGAP-IG) («Рук... more

Download (391)

View PDF (624)

Comfort for Kids in the Time of Ebola : Mental Health Liberia

World Bank (2018) C1

The 2014-2015 outbreak of Ebola virus disease (EVD) in Liberia resulted in over 10,000 cases and 5,000 deaths. Recognizing the importance of addressing children’s trauma, the Ebola recovery and restoration trust fund (EERTF) funded the implementation of a Comfort for kids (C4K) program which encou... more

Download (259)

View PDF (262)

Antidepressant medication in comparison with psychological treatment for moderate to severe depressive disorder
recommended

World Health Organization WHO (2015) C_WHO

Q7. SCOPING QUESTION: In adults with moderate-severe depressive disorder, what is the effectiveness and safety of antidepressant medication (ADM) in comparison with psychological treatment? The WHO mhGAP programme’s existing guidelines recommend that either structured brief psychological treatm... more

Download (293)

View PDF (448)

Persistent Global Acute Malnutrition

Young, H., Marshak, A. Feinstein International Center (2017) C3

A discussion paper on the scope of the problem, its drivers, and strategies for moving forward for policy, practice, and research In many protracted emergencies, the prevalence rates of global acute malnutrition (GAM) regularly exceed the emergency threshold of > 15% of children with acute malnutri... more

Download (2938)

View PDF (1148)

GUIDELINES FOR GOOD CLINICAL TRIAL PRACTICE IN ZIMBABWE

Medicines Control Authority of Zimbabwe (MCAZ) (2012) C2

Download (112)

View PDF (144)

Network of WHO Collaborating centers for trachoma

World Health Organization WHO (2016) C_WHO

International commitment to eliminate trachoma as a public health problem worldwide is supported by resolution WHA51.11 of the World Health Assembly .1 Important progress towards this goal has been made by harnessing the mostly informal relationships that exist between partners including Member Stat... more

Download (112)

View PDF (135)

Network of WHO Collaborating centres for trachoma

World Health Organization WHO (2016) C_WHO

SECOND MEETING REPORT DECATUR, GA, USA, 26 JUNE 2016

Download (102)

View PDF (632)

Serious adverse events following treatment of visceral leishmaniasis: A systematic review and meta-analysis

Singh-Phulgenda, S., Dahal, P., Ngu, R. et al. PLOS Neglected Tropical Diseases (2021) C1

Despite a historical association with poor tolerability, a comprehensive review on safety of antileishmanial chemotherapies is lacking. We carried out an update of a previous systematic review of all published clinical trials in visceral leishmaniasis (VL) from 1980 to 2019 to document any reported ... more

Download (245)

View PDF (329)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (196)

View PDF (150)

WHO guideline on the prevention and management of wasting and nutritional oedema (acute malnutrition) in infants and children under 5 years

World Health Organization WHO (2023) C_WHO

Today, the World Health Organization (WHO) is advancing the global fight against acute malnutrition in children under 5 with the launch of its new guideline on the prevention and management of wasting and nutritional oedema (acute malnutrition). This milestone is a crucial response to the persistent... more

Download (24)

View PDF (20)

The Treatment of Heart Failure with Reduced Ejection Fraction

Berliner, D.; Hänselmann, A.; Bauersachs, J. Deutsches Ärzteblatt International (2020) CC

Background Chronic congestive heart failure is a common condition that, if untreated, markedly impairs the quality of life and is associated with a high risk of recurrent hospitalization and death. Methods This review is based on articles retrieved by a selective search in PubMed, as well as on r... more

Download (24)

View PDF (23)

Preventing the next Pandemic: the Case for Investing in Circulatory Health

Global Coalition for Circulatory Health (2024) CC

The Coronavirus Disease 2019 (COVID-19) has had a continuous and robust impact on world health. The resulting COVID-19 pandemic has had a devastating physical, mental and fiscal impact on the millions of people living with noncommunicable diseases (NCDs), as they have a higher risk of severe illness... more

Download (14)

View PDF (12)

Primary and Secondary Prevention of Ischemic Stroke

Paciaroni, M.; Bogousslavsky, J. European Neurology (2010) CC

Prevention of stroke and transient ischemic attack includes both conventional approaches to vascular risk factor management (blood pressure lowering, cholesterol reduction with statins, smoking cessation and antiplatelet therapy) and more specific interventions, such as carotid revascularization or... more

Download (21)

View PDF (19)

Cardiac arrhythmias in low- and middle-income countries

Mkoko, P.; Bahiru, E.; Ajijola, O.A. et al. Cardiovascular Diagnosis and Therapy (2019) CC

Many low- and middle-income countries (LMICs) are undergoing an epidemiological transition. With an improvement in socioeconomic conditions and an aging population, cardiovascular diseases (CVDs), like cardiac arrhythmias, are expected to increase in these countries. However, there are limited studi... more

Download (26)

View PDF (15)

Protection from a Single Dose of HPV Vaccine A major public health impact from IARC studies of vaccine efficacy

World Health Organisation (WHO) (2023) C_WHO

Protection from a Single Dose of HPV Vaccine A major public health impact from IARC studies of vaccine efficacy.

Download (21)

View PDF (27)

Effectiveness of a diabetes program based on digital health on capacity building and quality of care in type 2 diabetes: a pragmatic quasi-experimental study

Moreas Morelli, D.; Rubinstein, F.; Santero, M.; et al. BMC Health Services Research, part of Springer Nature (2023) CC2

Health systems in Latin America face many challenges in controlling the increasing burden of diabetes. Digital health interventions are a promise for the provision of care, especially in developing countries where mobile technology has a high penetration. This study evaluated the effectiveness of th... more

Download (23)

View PDF (20)

Appropriate use and withdrawal of inhaled corticosteroids (ICS) in patients with chronic obstructive pulmonary disease (COPD)

Román-Rodríguez, M.; Tsiligianni, I.; Wiliams, S.; et al. International Primary Care - Respiratory Group (2020) CC2

The document "Appropriate use and withdrawal of inhaled corticosteroids (ICS) in patients with chronic obstructive pulmonary disease (COPD)" from the IPCRG provides guidance on when to start, adjust, or discontinue ICS in COPD treatment. It highlights the benefits and risks, emphasizing personalized... more

Download (25)

View PDF (26)

Supported self-management for asthma

Hinnock, H. Breathe (2015) CC

This articel summarises the evidence base underpinning supported self-management for asthma. It provides clinicians with a practical approach to providing supported self-management for asthma and suggests an appropriate strategy for implementing supported self-management.

Download (12)

View PDF (15)

Individual- and Facility-Level Factors Associated with Facility Testing among Men in Malawi: Findings from a Representative Community Survey

Balakasi, K.; Nichols, B. E.; Mphande, M.; et al. (2021) CC2

Men are underrepresented in HIV testing services throughout sub-Saharan Africa. HIV testing is critical to achieve the UNAIDS 95-95-95 goals, as it is the first entry point to HIV care. In Malawi, an estimated 14% of HIV positive men are undiagnosed, while only 6% of HIV positive women remain undiag... more

Групповая интерперсональная терапия (ипт) при депрессии recommended

Antidepressant medication in comparison with psychological treatment for moderate to severe depressive disorder recommended

Групповая интерперсональная терапия (ипт) при депрессии
recommended

Antidepressant medication in comparison with psychological treatment for moderate to severe depressive disorder
recommended